You can buy or sell MTZPY and other stocks, options, ETFs, and crypto commission-free!
Mitsubishi Tanabe Pharma Corp. engages in the research, development, manufacture, and sale of pharmaceutical products. Its products include Remicade, Ceredist, Talion, Kremezin, Maintate, Simponi, Lexapro, Tenelia, Tetrabik, and Imusera. Read More The company operates through Pharmaceuticals segment. Mitsubishi Tanabe Pharma was founded by Gohei Tanabeya in 1678 and is headquartered in Osaka, Japan. MTZPY is listed on the Pink Current market tier. OTC market data is provided by OTC Markets Group, Inc (otcmarkets.com).
52 Week High
52 Week Low
Akebia Therapeutics Announces Preliminary Full-Year 2018 Financial Results and Business Highlights
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced preliminary financial results for the full year ended December 31, 2018 and business highlights. “2018 was a transformational year for Akebia,” said John P. Butler, President and Chief Executive Officer of Akebia Therapeutics. “We successfully executed a number of strategic initiatives to a...
The Motley FoolMar 12
Why Akebia Therapeutics Is Soaring Today
What happened Shares of Akebia Therapeutics (NASDAQ:AKBA) were soaring 14.9% higher as of 10:53 a.m. EDT on Tuesday. The biopharmaceutical company announced positive results earlier in the day from two phase 3 clinical studies evaluating vadadustat in treating anemia due to chronic kidney disease (CKD). These studies were conducted by Akebia's commercialization collaboration partner in Japan, Mitsubishi Tanabe Pharma Corporation (MTPC). So what One of the phase 3 clinical studies was conducted on Japanes...